Quest Diagnostics (DGX) Getting Somewhat Positive Media Coverage, Accern Reports
Media headlines about Quest Diagnostics (NYSE:DGX) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quest Diagnostics earned a news impact score of 0.21 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.6912782067086 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- American Outdoor Brands (AOBC) At $14.10 Forms Bottom; Quest Diagnostics (DGX) SI Decreased By 1.87% – Hill Country Times (hillcountrytimes.com)
- Some hot names on Wall Street: The Coca-Cola Company (KO), Quest Diagnostics Incorporated (DGX) – Market Movers (financialqz.com)
- Quest Diagnostics : Completes Acquisition of Shiel Medical Laboratory from Fresenius Medical Care (4-traders.com)
- Quest Diagnostics Buys Fresenius Medical’s Shiel Laboratory (zacks.com)
- Contrasting Quest Diagnostics (DGX) and LifePoint Health (LPNT) (americanbankingnews.com)
A number of equities research analysts have commented on DGX shares. ValuEngine upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Canaccord Genuity restated a “buy” rating and set a $118.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, September 13th. Raymond James Financial restated a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Credit Suisse Group reduced their price target on Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating for the company in a report on Thursday, September 28th. Finally, Zacks Investment Research lowered Quest Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the stock. Quest Diagnostics currently has a consensus rating of “Hold” and an average target price of $106.28.
Shares of Quest Diagnostics (NYSE DGX) traded up $1.87 during trading on Friday, hitting $98.99. The stock had a trading volume of 1,398,548 shares, compared to its average volume of 1,026,451. The firm has a market cap of $13,240.12, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 2.02 and a beta of 0.60. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. Quest Diagnostics has a fifty-two week low of $90.10 and a fifty-two week high of $112.96.
Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.92 billion. During the same period in the previous year, the company earned $1.37 EPS. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. equities research analysts predict that Quest Diagnostics will post 5.65 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be issued a $0.45 dividend. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 annualized dividend and a yield of 1.82%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.74%.
TRADEMARK VIOLATION WARNING: “Quest Diagnostics (DGX) Getting Somewhat Positive Media Coverage, Accern Reports” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/quest-diagnostics-dgx-getting-somewhat-positive-media-coverage-accern-reports/1766595.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.